Epigenetic Reactivation of Lineage Differentiation to Target Leukemia

Transcriptional Control as a Therapeutic Strategy in Acute Myeloid Leukemia

: Acute myeloid leukemia (AML) is driven by dysregulated transcription factors (TFs) that disrupt hematopoietic differentiation, promote leukemic self-renewal, and confer therapy resistance. Key TFs including C/EBP α , PU.1, RUNX1, GATA2, EVI1, PML-RAR α fusion protein, p53, c-Myc and ERG are altered through mutations,...

IRF1-driven chromatin and transcriptional regulation determines the anti-tumor responses to all-trans retinoic acid across cancer types.

All-trans retinoic acid (ATRA) is a potent differentiation inducer successfully used to treat acute promyelocytic leukemia (APL), with its therapeutic efficacy traditionally attributed to targeting the PML/RARα fusion oncoprotein. ATRA also exhibits anti-tumor activity in multiple non-APL malignancies. However, PML/RAR...

SETD5 regulates leukemic initiation and infiltration in T-cell acute lymphoblastic leukemia.

It is demonstrated that SETD5 contributes to T-ALL progression by regulating transcriptional programs that contribute to leukemic cell migration and infiltration, suggesting that SETD5-associated transcriptional programs warrant further investigation as potential vulnerabilities in T-ALL.

KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells.

Targeting the Epigenetic–Immune Axis in Acute Myeloid Leukemia: Current Advances and Future Directions

Integrative enhancer discovery identifies functional enhancer dependencies in pediatric acute myeloid leukemia